Medicines
Update of 06/02/2026
LACRIFLUID SINGLE-DOSE®
carbomer 980
Forms and presentations
Eye drops in solution at 0,13 % (colourless, translucent solution): Single-dose containers, box of 60 (in sachets of 5).Composition
| single-dose p | |
| Carbomer 980
|
0,52 mg |
Indications
Symptomatic treatment of dry eye.Dosage and administration
DosageInstil one drop of eye drops into the lower conjunctival sac, 1 to 3 times a day, at regular intervals, depending on the eye disorders.
- Paediatric population:
- Children and adolescents up to the age of 18 years.
- The safety and efficacy of Lacrifluid 0,13 %, eye drops in solution in a single-dose container, at the recommended dosage for adults, have been established by clinical experience, but no clinical study data are available.
Method of administration:
Ophthalmic use.
Each single-dose container contains a sufficient quantity of eye drops to treat both eyes.
-
The patient will be advised:
- to avoid contact of the tip with the eye or eyelids;
- to discard the single-dose container after use.
- to avoid contact of the tip with the eye or eyelids;
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section Composition.Warnings and precautions
Do not inject, do not swallow.
These eye drops in a single-dose container do not contain a preservative; an already opened single-dose container must not be kept for later use.
If symptoms persist or worsen, the patient must be re-examined by a doctor.
Interactions
If concomitant treatment with another eye drop is given, wait 15 minutes between the two instillations.
Fertility, pregnancy and breastfeeding
This medicine may be used, if needed, in pregnant women and during breastfeeding.
Driving and using machines
Vision may be blurred for a few minutes after instillation.Adverse effects
Possibility of:- visual disturbance, transient burning or stinging sensation after instillation until the eye drops spread evenly over the surface of the eye;
- sensation of sticky eyelids;
- irritation or hypersensitivity reactions.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.
Pharmacodynamics
Pharmacotherapeutic class: artificial tear substitute (ATC code: S01XA20; S: sensory organs).
- Eye drops in solution based on a high molecular weight hydrophilic polymer (carbomer 980).
- Thanks to its physical properties, the eye drops in solution form a transparent, lubricating and wetting film on the surface of the eye, which temporarily compensates for insufficient tears.
- These eye drops have a neutral pH and are slightly hypotonic to tears.
- Their viscosity is higher than that of an artificial tear, which results in a less frequent administration frequency.
Pharmacokinetics
Due to the relatively large size of the carbomer molecule, penetration through the cornea is unlikely.
Storage conditions
- Shelf life
- 3 years.
Discard the single-dose container after use.
HANDLING/DISPOSAL INSTRUCTIONS
No special requirements.
Prescription, supply and reimbursement
| Marketing authorisation (AMM) | 3400937689021 (2006, SmPC rev 17.01.2018). |
| Price: | 5,50 euros (60 unit-dose vials). |
| Reimbursed by Social Security at 65 %. Collective. | |
EUROPHTA Laboratories
2, rue du Gabian. MC 98000 Monaco
Tel: 00 377 97 77 72 72. Fax: 00 377 97 77 72 70
Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.